Vision Disorders is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Vision Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Vision Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vision Disorders overview

Vision disorders are characterized by poor or unclear vision in an eye that is otherwise physically normal. It may be caused by a loss of visual acuity, where the eye does not see objects as clearly as usual. Leading causes of vision impairment and blindness include refractive errors, cataracts, diabetic retinopathy, glaucoma, age-related macular degeneration. Symptoms include changes in iris color, blurred vision, double vision, sudden or recurrent eye pain, sudden changes in vision, inability to distinguish certain colors, loss of side vision.

For a complete picture of PTSR and LoA scores for drugs in Vision Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.